South Africa is drafting new standards for compounded weight-loss drugs, the pharmacy-made versions of injections such as semaglutide and tirzepatide. The Pharmacy Council and the medicines regulator SAHPRA say they want to clarify where legitimate, patient-specific compounding ends and unlicensed manufacturing begins. The plan was outlined on 14 October 2026, and it follows a string of enforcement steps over the past two years. This timeline explains what is legal today, what is only proposed, and where the disputes lie.
Compounded weight-loss drugs in South Africa: key takeaways
- Proposed: revised standards, expected before the council in February and published in March.
- Existing: compounding is limited to named patients with a valid prescription, per the regulators.
- Enforcement: a joint inspection of a Pretoria compounder on 26 May 2026 led to seizures and a recall order.
- Litigation: Novo Nordisk reports an interim court order against the same company in June 2026.
A timeline of compounded weight-loss drugs enforcement
- November 2024: SAHPRA warns about compounded, substandard and falsified GLP-1 products sold online and through informal channels.
- 26 May 2026: SAHPRA and the Pharmacy Council announce the Silverton, Pretoria inspection.
- 22 June 2026: a Pretoria High Court interim order, as reported by the applicant.
- 14 October 2026: the Pharmacy Council describes the revision of standards at a roundtable.
What is legal today for compounded weight-loss drugs
The regulators’ consistent message is that compounding means preparing a medicine for an individual patient on a valid prescription. It cannot be used for large-scale manufacture, advertising or distribution of unregistered medicines, they say, citing the Medicines and Related Substances Act 101 of 1965. In SAHPRA’s November 2024 position, SAHPRA added that compounding with an active ingredient not found in a registered product is illegal. It also said compounded semaglutide had not been verified by SAHPRA, so it was unknown whether the ingredient matched the registered one.
What the standards on compounded weight-loss drugs are meant to settle
Vincent Tlala, the Pharmacy Council’s Registrar and CEO, said the concern is pharmacies acting as small-scale manufacturers and compounding in anticipation of demand. SAHPRA’s Daphney Fafudi said the revised standards and guidelines aim to make clear what is permissible. The implication is that today’s rules are contested in practice. The standards’ text has not been published, and the timetable as reported gives February for the council and March for publication without naming a year. By the calendar, that means 2027.
Why regulators worry about compounded weight-loss drugs
The inspection findings explain the unease. According to the government news release of 26 May, regulators said the Silverton site appeared to supply semaglutide, tirzepatide and combination products widely under the compounding label, with illegally imported ingredients, no analytical testing and unsuitable sterile conditions. SAHPRA’s statement on unregistered GLP-1 medicines added that it had received reports of adverse events, including hospitalisations. Sterile injectables made from complex ingredients leave little room for error, which is the reason regulators stress testing and quality systems. These remain the regulators’ findings, and no counts of patients or events were published.
Who can act on compounded weight-loss drugs, and how
Two different levers are in play. SAHPRA enforces the medicines law, and in the Pretoria case it seized finished products and ordered a recall of anything already distributed through healthcare providers, pharmacies and other channels. The Pharmacy Council regulates the profession, and said it would take further action against pharmacy professionals involved, with removal from the register among the possible outcomes. SAHPRA’s chief executive, Dr Boitumelo Semete-Makokotlela, said the authority would continue to take “decisive regulatory and enforcement action” against any entity that breaks the law, and the regulators also flagged concern about promotion to healthcare providers and consumers.
The court dispute: one side’s account
A press release issued for Novo Nordisk South Africa says the Pretoria High Court, on 22 June 2026, granted an interim interdict stopping iDexis from manufacturing, supplying, marketing or advertising compounded semaglutide containing an unregistered ingredient, and from claiming SAHPRA approval. That is Novo Nordisk’s account of an interim order. We have not assessed iDexis’s response, and an interim order is not a final ruling on the merits.
Brand names and compounded weight-loss drugs: a caution
Weight-loss medicines are often discussed by brand name, which can blur what each product is registered for. SAHPRA’s 2024 statement said Ozempic was registered for type 2 diabetes and cardiovascular risk reduction in adults with the disease and was not registered for weight management, and that Mounjaro was not registered for weight management. Registrations change, and we have not verified the present position of Wegovy or Zepbound in South Africa, so we make no claim about them. The regulator’s register is the place to check.
Risks and caveats on compounded weight-loss drugs
- Standards are proposed; none is yet binding.
- Several details come from one party’s release or from regulators’ own statements.
- Registration status of branded products has changed before and may again; check SAHPRA’s register.
- This is not legal or medical advice.
In our assessment, the pattern across 2024 to 2026 is a regulator moving from warnings to inspections to standard-setting, and the open question for compounded weight-loss drugs is whether the final standards will be specific enough to end the disputes over interpretation. See also India Pharma Market Growth Surges, but Datasets Disagree. More in our pharmaceutical coverage.
What to watch next on compounded weight-loss drugs
- Council submission in February and publication in March.
- Whether draft text goes out for comment.
- Further court steps and any appeal outcomes.
- More inspections and disciplinary actions.
Frequently asked questions
What are compounded weight-loss drugs?
Pharmacy-prepared versions of medicines such as semaglutide or tirzepatide, made outside the registered product.
Is compounding allowed in South Africa?
Regulators say yes, but only for an individual patient on a valid prescription.
When will the new standards appear?
Publication is targeted for March, after a February council submission.
Who can discipline pharmacists?
The Pharmacy Council, which has said removal from the register is among the possible outcomes in the Pretoria case.
How we reported this: we relied on SAHPRA statements, a government news release, a press release issued for Novo Nordisk South Africa and remarks at the 14 October 2026 roundtable. Last updated: 16 October 2026. This article is news reporting and not legal or medical advice.
